HanAll Biopharma Co., Ltd. (KRX: 009420.KS), a global biopharmaceutical company committed to discovering and developing ...

A MAN in Bromsgrove with a rare autoimmune disease has welcomed news of an historic medical milestone which has seen blood ...

Myasthenia gravis is a neuromuscular junction disorder with a hallmark of progressive muscle weakness and frequent ...

Generalized myasthenia gravis (gMG) affects most patients through a handful of well-characterized neuromuscular junction ...

Higher Quantitative Myasthenia Gravis-Revised (QMG) scores, indicating more severe disease based on clinician ratings, have been associated with frequent exacerbations. New data from the ...

Belgian biopharma UCB has been given the green light by the FDA for Zilbrysq as a treatment for generalised myasthenia gravis (gMG ... and neuromuscular disease. Zilbrysq (zilucoplan), billed ...

"By the age of 10, about 90 percent will develop Myasthenia gravis disease, which can lead to heart failure," Amir explains. While the breed’s charm might make it worth the medical commitment ...

When we use autologous CAR T cells, we have to collect the cells from the patient's blood and turn them into CAR T cells, and that's a process that takes time. It could take 4 weeks or longer to ...